Riskpilot← Back to searchSign inGet full accessArcede Pharma AB
ABIn liquidationOrg 5566507330LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20031 employees
Revenue 2024
SEK 0
EBITDA margin
—
+49% vs 2023
Equity ratio
69.1%
Financial strength
Net profit 2024
SEK -23,4M
+25% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -3,8M | +49% |
| Net profit | SEK -23,4M | +25% |
| Total assets | SEK 3,1M | -87% |
| Equity | SEK 2,2M | -90% |
| Employees | 1 | — |
Legal name
Arcede Pharma AB
Org number
5566507330
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 oktober 2003
Share capital
SEK 14 450 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska, direkt eller indirekt, bedriva forskning, utveckling, tillverkning och försäljning av läkemedel för luftvägssjukdomar samt ävensom bedriva annan därmed förenlig verksamhet.
Address
Lund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0 | 0 | 0 | 0 | 56 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −6 | −6 | −6 | −6 | −6 | −6 | — | −9 | −7 453 | −3 769 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −23 903 | −19 634 |
| EBIT | −6 | −6 | −6 | −6 | −6 | −6 | 0 | −9 | −31 356 | −23 403 |
| Net financials | — | — | — | — | — | — | — | — | 1 | −1 |
| Profit before tax | −6 | −6 | −6 | −6 | −6 | −6 | 0 | −9 | −31 354 | −23 404 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −6 | −6 | −6 | −6 | −6 | 0 | −9 | −31 354 | −23 404 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 100 | 94 | 88 | 83 | 77 | 72 | 73 | 49 555 | 24 886 | 3 144 |
| Equity | 94 | 88 | 83 | 77 | 72 | 66 | 66 | 49 546 | 21 181 | 2 172 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 6 | 6 | 5 | 6 | 6 | 6 | 7 | 9 | 3 706 | 973 |
| Total debt | 6 | 6 | 5 | 6 | 6 | 6 | 7 | 9 | 3 706 | 973 |
EBITDA margin
-376900000.0%
This company
15.8%
Market median
-2385443138% vs market
20152024
Equity ratio
69.1%
This company
38.2%
Market median
+81% vs market
20152024
Return on equity
-1077.5%
This company
18.4%
Market median
-5956% vs market
20152024
Net profit margin
-2340400000.0%
This company
8.1%
Market median
-28893827260% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.45×
This company
0.62×
Market median
+27% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KE Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
LO Liquidator | Liquidator | 2024 | — | — |
MS Chief Auditor | Chief Auditor | 2022 | — | — |
ME Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
CO Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Respiratorius AB (publ) | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Respiratorius AB (publ)
Arcede Pharma AB Board members of Arcede Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kurt Erik Magnusson | Chief Executive Officer | 0 companies |
| Lars Olof Henrik Andersson | Liquidator | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Mia Elisabeth Sandberg Lundblad | Chief Executive Officer | 0 companies |
| Carl Olov Strömberg | Audit | 0 companies |
| Lars Christer Fredrik Fåhraeus | Deputy Board Member | 0 companies |
| Johanna Kristina Asklin | Board of Directors | 0 companies |
| Gustav Ingemar Kihlström | Chairman | 0 companies |
| Laurent Pacheco | Board of Directors | 0 companies |
| Lars Johan Lennart Drott | Board of Directors | 0 companies |
| Åsa Margaretha Kornfeld | Board of Directors | 0 companies |
| Kristina Margit Magdalena Drott | Deputy Board Member | 0 companies |